The earnings call presented a mixed outlook with strong cash flow and innovation driving positive sentiment, but challenges in core revenue growth and specific segment declines, particularly in Diagnostics and the China market, created headwinds.

Company Guidance

During the fourth quarter 2024 earnings call, Danaher Corporation provided comprehensive guidance for the upcoming year, reflecting both achievements and anticipated challenges. The company reported sales of $6.5 billion for the quarter, with a 1% core revenue growth, and adjusted diluted net earnings per share of $2.14, up 2.4% year-over-year. For the full year 2024, sales totaled $23.9 billion with a 1.5% decline in core revenue. The adjusted operating profit margin was flat at 28.6%, while free cash flow reached $5.3 billion, marking a conversion ratio of approximately 135%. Looking forward to 2025, Danaher projected a 3% core revenue growth with a 2% revenue headwind due to currency fluctuations and anticipated an adjusted operating profit margin of 28.5%. The company also highlighted strategic investments and innovations, including acquisitions and new product launches in biotechnology, life sciences, and diagnostics, aiming for sustainable long-term growth and shareholder value.

Strong Free Cash Flow and Share Repurchases

Danaher Corporation generated $5.3 billion of free cash flow in 2024, marking the 33rd consecutive year of free cash flow to net income conversion exceeding 100%. Additionally, the company deployed approximately $7 billion towards repurchasing 28 million shares of its common stock.

Bioprocessing Business Momentum

The bioprocessing business exhibited high-single-digit core revenue growth and sustained positive momentum with high-single-digit sequential order growth for six consecutive quarters.

Innovative Product Launches

Significant innovations were introduced, such as Cytiva's Sefia cell therapy manufacturing platform, Beckman Coulter's Cydem VT Automated Cell Culture System, and the DxI 9000 immunoassay analyzer, enhancing customer capabilities and advancing critical healthcare solutions.

Adjusted Earnings Per Share Increase

Adjusted diluted net earnings per common share increased by 2.4% year-over-year to $2.14 in the fourth quarter.

---

Danaher (DHR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DHR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 17, 2025	2025 (Q1)	1.62 / -	1.92	―	―	―
Jan 29, 2025	2024 (Q4)	2.16 / 2.14	2.09	2.39% (+0.05)
Oct 22, 2024	2024 (Q3)	1.57 / 1.71	2.02	-15.35% (-0.31)
Jul 23, 2024	2024 (Q2)	1.57 / 1.72	1.817	-5.34% (-0.10)
Apr 23, 2024	2024 (Q1)	1.72 / 1.92	2.092	-8.22% (-0.17)
Jan 30, 2024	2023 (Q4)	1.91 / 2.09	2.544	-17.85% (-0.45)
Oct 24, 2023	2023 (Q3)	1.81 / 2.02	2.269	-10.97% (-0.25)
Jul 25, 2023	2023 (Q2)	1.78 / 1.82	2.446	-25.72% (-0.63)
Apr 25, 2023	2023 (Q1)	2.00 / 2.09	2.446	-14.47% (-0.35)
Jan 24, 2023	2022 (Q4)	2.26 / 2.54	2.384	6.71% (+0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DHR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 29, 2025	$247.84	$223.73	-9.73%
Oct 22, 2024	$271.77	$260.97	-3.97%
Jul 23, 2024	$250.35	$263.61	+5.30%
Apr 23, 2024	$235.32	$252.30	+7.22%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---